Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
22 results
D1.326 - Six Cases of Adult-Onset PFAPA (Periodic Fever, Aphthous stomatitis, Pharyngitis, and Cervical Adenopathy) Syndrome
D1.327 - A Rare Primary Immunodeficency Hidden in Autoimmunity: Heterozygote CD3G variant in a 49-year-old Female Patient
D1.332 - Hereditary Angioedema in Ukraine
D1.333 - A Newly Identified POLE1 Deficiency (FILS Syndrome) Patient with Severe Immunodeficiency: Clinical Course and Treatment Approach
D1.334 - A Novel Variant in ALPS Type V Due to CTLA-4 Deficiency: A Case Presenting with Cytopenia
D1.335 - TeloNet is born; why immunologists should know about telomere disorders
D1.336 - Sirolimus for the treatment of the Immunodeficiency Linked to PIK3CD (APDS1)
D1.337 - Clinical features of patients submitted to immunoglobulin replacement therapy in an outpatient regimen at a tertiary hospital during 2024
D1.308 - Case report: challenges in a long-term prophylaxis in hereditary angioedema (HAE)
D1.310 - Phenotypes of patients with Hereditary Angioedema (HAE): a case series
D1.311 - Treatment Dilemmas in CARMIL2 Deficiency
D1.312 - Acquired C1-inhibitor deficiency angioedema treated with lanadelumab: a case series
D1.313 - Inborn Error of Immunity Associated Inflammatory Bowel Disease at a Tertiary Care Center
D1.315 - Classifying the unclassifiable: diagnosis, characterization, and management of adults with unclassified primary antibody deficiency (unPAD)
D1.316 - Lessons Learned from the Diagnosis and Management of a female pediatric patient with NCF2 Mutations and Chronic Granulomatous Disease
D1.317 - A Retrospective Analysis of Dengue-Associated Hemophagocytic Lymphohistiocytosis in a Dengue-Endemic Country
D1.318 - Extending Lanadelumab Dosing Intervals to Every 4 Weeks With Sustained Effectiveness for Hereditary Angioedema Attack Prevention: An Analysis From the Final ENABLE Study Data
D1.319 - The Silent Threat of Hereditary Angioedema in Children: Single Center Experience
D1.322 - A Prescription for Lower Immunity: The Hidden Cost of Certain Psychiatric Medications
D1.323 - Concurrence of essential mixed cryoglobulinemia and cold agglutinin disease: a matter of shared light chains. Case series and literature review
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download